Shilpa Medicare (SML) has entered into a binding agreement with NXI Therapeutics AG, a Swiss-based pharmaceutical company, for the development and supply of a New Chemical Entity (NCE). According to reports from Business Standard, this strategic collaboration represents a significant step in SML's expansion into specialized pharmaceutical development and manufacturing. The company has formally informed about this development through its filings submitted to BSE, as reported in the latest company disclosures.
Under the terms of the agreement, SML will support both development and long-term commercial supply of the NCE. As reported by Business Standard, the collaboration encompasses first-in-human clinical studies and includes GMP manufacturing capabilities. This comprehensive approach positions SML to handle the entire lifecycle of the pharmaceutical product from development through commercial supply, providing the company with end-to-end capabilities in specialized therapeutic development.
The partnership with NXI Therapeutics AG, based in Basel, Switzerland, represents SML's entry into international pharmaceutical development and manufacturing. According to the report, this collaboration allows SML to expand its capabilities beyond traditional pharmaceutical manufacturing into specialized therapeutic development, potentially opening new revenue streams and market opportunities for the company. The strategic positioning enables SML to compete in the global pharmaceutical market through its partnership with the Swiss company.
